new_0222_0617|INZY|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|sga_expense|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|short_interest|forward_pe_ratio|forward_pe_ratio_1y|forward_ps_ratio|forward_ps_ratio_1y|quarterly_eps_estimates|quarterly_sales_estimates|quarterly_eps_surprise|quarterly_sales_surprise|quarterly_eps_actual|quarterly_sales_actual|sales_est_0y|sales_est_1y|price_target|consensus_recommendation|price_target_num_est|eps_est_0y|eps_est_1y|r_and_d_expense|reconciled_depreciation|interest_expense_non_operating|land_and_improvements|buildings_and_improvements|other_properties|machinery_furniture_equipment|price_next_month|price_second_month
new_0222_0617|INZY|1|Inozyme Pharma Inc Total Current Assets (Quarterly) (USD)|Inozyme Pharma Inc Cash and Short Term Investments (Quarterly) (USD)|Inozyme Pharma Inc Inventories (Quarterly) (USD)|Inozyme Pharma Inc Net PP&E (Quarterly) (USD)|Inozyme Pharma Inc Goodwill and Intangibles (Quarterly) (USD)|Inozyme Pharma Inc Total Liabilities (Quarterly) (USD)|Inozyme Pharma Inc Total Current Liabilities (Quarterly) (USD)|Inozyme Pharma Inc Total Long Term Liabilities (Quarterly) (USD)|Inozyme Pharma Inc Total Deposits (Quarterly) (USD)|Inozyme Pharma Inc Book Value (Quarterly) (USD)|Inozyme Pharma Inc Retained Earnings (Quarterly) (USD)|Inozyme Pharma Inc Treasury Stock (Quarterly) (USD)|Inozyme Pharma Inc EV to Revenues|Inozyme Pharma Inc EV to Earnings|Inozyme Pharma Inc EV to Free Cash Flow|Inozyme Pharma Inc EV to Assets (Quarterly)|Inozyme Pharma Inc PS Ratio|Inozyme Pharma Inc PE Ratio|Inozyme Pharma Inc Price to Book Value|Inozyme Pharma Inc PEG Ratio|Inozyme Pharma Inc Debt to Equity Ratio|Inozyme Pharma Inc Dividend Yield|Inozyme Pharma Inc Shareholder Yield (TTM)|Inozyme Pharma Inc Percent of Shares Outstanding Short|Inozyme Pharma Inc Total Receivables (Quarterly) (USD)|Inozyme Pharma Inc Total Payables (Quarterly) (USD)|Inozyme Pharma Inc Total Capital Stock (Quarterly) (USD)|Inozyme Pharma Inc Return on Invested Capital|Inozyme Pharma Inc Quality Ratio Score|Inozyme Pharma Inc Momentum Score|Inozyme Pharma Inc Beta (1Y)|Inozyme Pharma Inc Sustainable Growth Rate (TTM)|Inozyme Pharma Inc Institutional Investor Ownership Percentage|Inozyme Pharma Inc Average Diluted Shares Outstanding (Quarterly)|Inozyme Pharma Inc Total Employees (Annual)|Inozyme Pharma Inc EPS Diluted (Quarterly) (USD)|Inozyme Pharma Inc SG&A Expense (Quarterly) (USD)|Inozyme Pharma Inc Shares Outstanding|Inozyme Pharma Inc Repurchase of Capital Stock (Quarterly) (USD)|Inozyme Pharma Inc Ordinary Shares Number (Quarterly)|Inozyme Pharma Inc Payout Ratio|Inozyme Pharma Inc Quick Ratio (Quarterly)|Inozyme Pharma Inc Normalized Diluted EPS (Quarterly) (USD)|Inozyme Pharma Inc Stock Buybacks (Quarterly) (USD)|Inozyme Pharma Inc Effective Tax Rate (TTM)|Inozyme Pharma Inc Return on Equity|Inozyme Pharma Inc Net Income (TTM) (USD)|Inozyme Pharma Inc Revenue (TTM) (USD)|Inozyme Pharma Inc Dividend Per Share (Quarterly) (USD)|Inozyme Pharma Inc Revenue (Quarterly) (USD)|Inozyme Pharma Inc Gross Profit (Quarterly) (USD)|Inozyme Pharma Inc Pre-Tax Income (Quarterly) (USD)|Inozyme Pharma Inc Net Income (Quarterly) (USD)|Inozyme Pharma Inc Net Interest Income (Quarterly) (USD)|Inozyme Pharma Inc Price (USD)|Inozyme Pharma Inc Total Return Price (USD)|Inozyme Pharma Inc Enterprise Value (USD)|Inozyme Pharma Inc 30-Day Average Daily Volume|Inozyme Pharma Inc 1 Year Price Returns (Daily)|Inozyme Pharma Inc Short Interest|Inozyme Pharma Inc PE Ratio (Forward)|Inozyme Pharma Inc PE Ratio (Forward 1y)|Inozyme Pharma Inc PS Ratio (Forward)|Inozyme Pharma Inc PS Ratio (Forward 1y)|Inozyme Pharma Inc Quarterly EPS Estimates (USD)|Inozyme Pharma Inc Quarterly Revenue Estimates (USD)|Inozyme Pharma Inc Quarterly EPS Surprise|Inozyme Pharma Inc Quarterly Revenue Surprise|Inozyme Pharma Inc Quarterly Actual EPS (USD)|Inozyme Pharma Inc Quarterly Actual Revenue (USD)|Inozyme Pharma Inc Revenue Estimates for Current Fiscal Year (USD)|Inozyme Pharma Inc Revenue Estimates for Next Fiscal Year (USD)|Inozyme Pharma Inc Price Target (USD)|Inozyme Pharma Inc Consensus Recommendation|Inozyme Pharma Inc Price Target Num Estimates|Inozyme Pharma Inc EPS Estimates for Current Fiscal Year (USD)|Inozyme Pharma Inc EPS Estimates for Next Fiscal Year (USD)|Inozyme Pharma Inc Research and Development Expense (Quarterly) (USD)|Inozyme Pharma Inc Reconciled Depreciation (Quarterly) (USD)|Inozyme Pharma Inc Non-Operating Interest Expense (Quarterly) (USD)|Inozyme Pharma Inc Land and Improvements (Quarterly) (USD)|Inozyme Pharma Inc Buildings and Improvements (Quarterly) (USD)|Inozyme Pharma Inc Other Properties (Quarterly) (USD)|Inozyme Pharma Inc Machine, Furniture & Equipment (Quarterly) (USD)||
new_0222_0617|INZY|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_per_share_metric|percent_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_USD_metric|figure_whole_USD_price|figure_money_USD_per_share_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric||
new_0222_0617|INZY|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|monthly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0617|INZY|5|91.2857142857|91.2857142857||91.2857142857||91.2857142857|91.2857142857|91.2857142857||91.2857142857|91.2857142857||||1.44584382872||||1.44571428571|||1.44584382872||15.25|91.2857142857|91.2857142857|91.2857142857|||30.6|30.6666666667|||91.4|167|91.4|91.4|34||91.2857142857|||91.4|91.375|||91.2857142857|||||91.4|91.4|91.4|1.44584382872|1.44584382872|1.44584382872|1.44836956522|1.4275862069|15.25||||1.44117647059|91.5|91.4|91.4||91.4|91.4|44.8333333333|44.8333333333|41.3846153846|21.52|41.3846153846|45.1|45.1|91.4|91.4|||91.5|91.2857142857|91.2857142857||
new_0222_0617|INZY|6|7|7||7||7|7|7||7|7||||397||||350|||397||36|7|7|7|||5|6|||10|1|10|10|14||7|||10|8|||7|||||10|10|10|397|397|397|368|145|36||||34|6|10|5||5|5|12|12|13|25|13|10|10|10|10|||2|7|7||
new_0222_0617|INZY|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily|daily|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly||
new_0222_0617|INZY|201903||||||||||||||||||||||||||||||||||15.1592||-0.3279|1.03||||||-0.3279|||||||||-4.971|-4.971|0.21||||||||||||||||||||||||4.134|0.019|||||||
new_0222_0617|INZY|201906||||||||||||||||||||||||||||||||||15.1592||-0.2753|1.064||||||-0.2753|||||||||-4.173|-4.173|0.394||||||||||||||||||||||||3.489|0.019|||||||
new_0222_0617|INZY|201909||||||||||||||||||||||||||||||||||15.1592||-0.2662|1.003||||||-0.2662|||||||||-4.035|-4.035|0.288||||||||||||||||||||||||3.317|0.02|||||||
new_0222_0617|INZY|201912|47.46|47.132||0.298||81.163|3.236|77.927||-33.219|-34.652||||||||||||||0.104|0.901||||||||15.1592||-0.4317|1.489|||20.3149|||-0.4317||||-19.723|||||-6.544|-6.544|0.214||||||||||||||||||||||||5.279|0.025||||0.308|0.053||
new_0222_0617|INZY|202003|74.963|74.54||0.374||4.909|4.909|||70.827|-60.149||||||||||||||0.044|1.569|0.001|||||||15.1592||-0.5104|1.5|||20.3149|||-0.5104||||-22.49|||||-7.738|-7.738|0.171||||||||||||||||||||||||6.406|0.025||||0.312|0.139||
new_0222_0617|INZY|202006|64.66|63.867||0.846||118.53|6.727|111.803||-50.019|-51.863||||-16.5098|||||||||0.2962|0.082|1.399||||||||20.3149|24|-0.4663|1.671|23.3649||20.3149|||-0.4663||||-27.79|||||-9.473|-9.473|0.071|19.55|19.55|392.9168|||69198|||||-3.63||-108.5399||-7.57||||36|1.25|3|-2.205|-1.635|7.877|0.026||||0.312|0.19|29.98|
new_0222_0617|INZY|202009|163.977|159.502||2.455||11.077|9.814|1.263||167.916|-79.958||||-14.5808||||3.6582|||||1.5378|0.252|3.665|0.002|||||||18.1015||-1.55|3.142|23.3649||23.3649|||-1.55|-116.988|||-51.85|||||-28.095|-28.095|0.064|26.29|26.29|454.7612|103835.5333||359299|||||-0.495||-14.8889||-0.5687||||36.6667|1.25|3|-2.735|-2.22|25.174|0.043||||0.334|0.31|22.97|26.02
new_0222_0617|INZY|202012|150.979|147.697||2.648||11.26|9.973|1.287||158.103|-91.076||||-9.1667||||3.0529|||||2.3136|0.155|3.069|0.002|||||||23.385|38|-0.4754|4.235|23.385||23.385|||-0.4754|1.016|||-56.424|||||-11.118|-11.118|0.064|20.64|20.64|334.9694|42847.2||541032|||||-0.49|||||||||1.25||||7.036|0.123||||0.339|0.541|21.04|20
new_0222_0617|INZY|202103|148.041|145.086||5.029||10.026|6.832|3.194||148.889|-102.126||||-7.4975||||3.1216|||||5.6439|0.122|1.709|0.002|||||||23.4295||-0.47|4.369|23.4737||23.4737|||-0.47||||-59.736|||||-11.05|-11.05|0.063|19.8|19.8|319.6933|58901.4||1324838|||||-0.51||7.8431||-0.47||||36.6667|1.25|3|-2.38|-2.65|6.603|0.158|||2.341|0.522|0.556|18.48|16.36
new_0222_0617|INZY|202106|140.962|137.464||4.859||9.985|6.972|3.013||138.274|-114.666||||-5.9819||||2.9047|||||5.5215|0.095|0.796|0.002|||2|2.4875|||23.4906||-0.53|4.435|23.5706||23.5706|||-0.53||||-62.803|||||-12.54|-12.54|0.058|17.04|17.04|264.179|77266.2667|-15.6439|1301462|||||-0.56||5.3571||-0.53||||36|1.25|3|-2.125|-2.27|8.22|0.167|||2.248|0.581|0.587|16.77|15.42
new_0222_0617|INZY|202109|130.579|125.283||4.743||11.772|8.943|2.829||125.974|-128.946||||-3.2562||||2.1772|||||0.9628|0.073|0.626|0.002|||2|1.6771|||23.6435||-0.6|4.916|23.6647||23.6647|||-0.6||||-48.988|||||-14.28|-14.28|0.047|11.59|11.59|148.9909|120419.3|-55.9148|227844|||||-0.57||-5.2632||-0.6||||32.25|1.25|4|-2.105|-2.185|9.346|0.167|||2.152|0.593|0.722|9.34|7.94
new_0222_0617|INZY|202112|||||||||||||||-0.7892||||1.2812|||||0.6465||||||1|0.5708||||||||||||||||||||||||6.82|6.82|36.1103|66718.9667|-66.9574|152994||||21519.1005|-0.605|||||||0.006|32.4|1.4|5||||||||||6.68|6.54
new_0222_0617|INZY|202203||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
new_0222_0617|INZY|202206||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
new_0222_0617|INZY|202209||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
new_0222_0617|INZY|202212||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||